Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers

Area of Science:

• Immunology
• Rheumatology
• Clinical Diagnostics

Background:

• Disease-specific autoantibodies are critical biomarkers in systemic sclerosis (SSc), enabling patient stratification based on severity and prognosis.
• Anti-nuclear antibodies (ANA) are strong predictors of SSc and digital microvascular damage, though ANA-negative SSc represents a distinct subtype with unique clinical features.
• Established biomarkers like anti-centromere, anti-Th/To, and anti-Topoisomerase I antibodies define specific SSc subsets and associated complications.

Purpose of the Study:

• To highlight the diagnostic and prognostic significance of various autoantibodies in systemic sclerosis (SSc).
• To discuss the clinical implications of novel and established autoantibodies, including their association with specific SSc subtypes and overlap syndromes.
• To emphasize the importance of accurate autoantibody detection for early diagnosis, patient stratification, and personalized treatment strategies.

Main Methods:

• Review of current literature on autoantibodies in systemic sclerosis (SSc).
• Analysis of the diagnostic utility and predictive value of autoantibodies in SSc patient stratification.
• Discussion of immunofluorescence assays and immunoprecipitation techniques for autoantibody identification.

Main Results:

• Anti-nuclear antibodies (ANA) are present in over 90% of SSc patients, predicting disease onset and microvascular damage.
• Specific autoantibodies (anti-Topoisomerase I, anti-RNA polymerase III) are linked to severe disease manifestations like diffuse skin thickening, digital ulcers, ILD, and cancer.
• Novel autoantibodies (anti-elF2B, anti-RuvBL1/2, anti-U11/U12 RNP, anti-BICD2) identify rare SSc subtypes with severe organ involvement.
• Autoantibodies such as anti-Ku, anti-U3RNP, and anti-PM/Scl are associated with SSc overlap syndromes and distinct clinical phenotypes.

Conclusions:

• Accurate detection and interpretation of SSc-specific autoantibodies and those associated with overlap syndromes are essential for precise patient stratification.
• Standardized methods for ANA detection and gold-standard immunoprecipitation for autoantibody identification are crucial.
• Further validation of novel autoantibodies in larger cohorts is needed to reduce the proportion of "seronegative" SSc patients and refine diagnostic and therapeutic approaches.